Abstract

Delayed-type cutaneous drug hypersensitivity is a T-cell mediated disease; the spectrum of conditions has been classified according to the phenotype and function of drug antigen-specific T-cells sub-sets. Importantly, this classification does not take into account tissue-specific cytokines such as interleukin-17 and interleukin-22. Both of these cytokines have been shown to play a role in numerous physiological and pathological processes. For example, elevated levels have been detected in patients with psoriasis and allergic contact dermatitis. To investigate this, we have focused on piperacillin, a β-lactam antibiotic used for the treatment of pulmonary exacerbations in patients with cystic fibrosis. Unfortunately hypersensitivity reactions (mean onset = 9.1 days; symptoms include maculopapular rash, fever and/or flu-like symptoms) to this drug develop in 26-50% of treated patients. Piperacillin-specific T-cell clones were generated from 3 lymphocyte transformation test positive hypersensitive patients and 4 healthy donors, following priming of naive T-cells against piperacillin-exposed dendritic cells, to characterize T-cell phenotype (CD and chemokine receptor expression) and function (proliferation and secretion of cytokines/cytolytic molecules [IFNγ, 13, 17, 22 by ELIspot]). Seventy six CD4+ and CD8+ clones were isolated from the hypersensitive patients and shown to proliferate in the presence of piperacillin. Drug stimulation was associated with the secretion of IFN-γ and IL13 from all clones. IL-22 secretion was detected from 64% and 75% of the CD4+ and CD8+ clones, respectively. In contrast, IL17 was not detected. Naive T-cells co-cultured with piperacillin and autologous dendritic cells showed concentration-dependent proliferation and cytokine (IFNγ, IL13 and IL22) secretion. CD4+ and CD8+ clones generated from the primed T-cells also secreted IFNγ, IL13 and IL22 (CD4+ 50%, CD8+ 67%) following piperacillin stimulation. CCR1, CCR4 and CCR10 were expressed on all clones. Other chemokine receptors expressed on a limited number of clones included CXCR3, CXCR6, CCR2 and CCR9. In conclusion, these data show the involvement of IL22 secreting T-cells in the pathogenesis of piperacillin hypersensitivity reactions in patients with cystic fibrosis.

Highlights

  • Delayed-type cutaneous drug hypersensitivity is a T-cell mediated disease; the spectrum of conditions has been classified according to the phenotype and function of drug antigen-specific T-cells sub-sets

  • We have focused on piperacillin, a b-lactam antibiotic used for the treatment of pulmonary exacerbations in patients with cystic fibrosis

  • Piperacillin-specific T-cell clones were generated from 3 lymphocyte transformation test positive hypersensitive patients and 4 healthy donors, following priming of naïve T-cells against piperacillin-exposed dendritic cells, to characterize T-cell phenotype (CD and chemokine receptor expression) and function

Read more

Summary

Introduction

Delayed-type cutaneous drug hypersensitivity is a T-cell mediated disease; the spectrum of conditions has been classified according to the phenotype and function of drug antigen-specific T-cells sub-sets. Detection of interleukin-22 secreting T-cells in piperacillin hypersensitive patients with cystic fibrosis From 6th Drug Hypersensitivity Meeting (DHM 6) Bern, Switzerland. This classification does not take into account tissue-specific cytokines such as interleukin-17 and interleukin-22.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.